Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KPTI 
Karyopharm Therapeutics Inc (KPTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: KPTI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $29.25
1 Year Target Price $29.25
| 2 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.57% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.20M USD | Price to earnings Ratio - | 1Y Target Price 29.25 |
Price to earnings Ratio - | 1Y Target Price 29.25 | ||
Volume (30-day avg) 6 | Beta 0.23 | 52 Weeks Range 3.51 - 16.95 | Updated Date 07/11/2025 |
52 Weeks Range 3.51 - 16.95 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -43.99% | Operating Margin (TTM) -110.8% |
Management Effectiveness
Return on Assets (TTM) -44.76% | Return on Equity (TTM) -891.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 159961520 | Price to Sales(TTM) 0.3 |
Enterprise Value 159961520 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 1.13 | Enterprise Value to EBITDA -1.85 | Shares Outstanding 8639900 | Shares Floating 7887109 |
Shares Outstanding 8639900 | Shares Floating 7887109 | ||
Percent Insiders 6.39 | Percent Institutions 42.62 |
Upturn AI SWOT
Karyopharm Therapeutics Inc
Company Overview
History and Background
Karyopharm Therapeutics Inc. was founded in 2008 and is a commercial-stage pharmaceutical company pioneering novel therapies for cancer and other diseases. It focuses on Selective Inhibitor of Nuclear Export (SINE) compounds.
Core Business Areas
- Oncology: Focuses on the development and commercialization of therapies for hematologic malignancies and solid tumors.
Leadership and Structure
Dr. Richard Paulson is the President and CEO. The company has a typical biotech structure with departments focused on research, development, commercialization, and administration.
Top Products and Market Share
Key Offerings
- XPOVIO (selinexor): XPOVIO is an oral Selective Inhibitor of Nuclear Export (SINE) compound approved for multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). Market share varies by indication and geography; specific figures are difficult to obtain due to competitive dynamics and limited public reporting. Competitors include Celgene/Bristol Myers Squibb, Amgen, Janssen, and Novartis, depending on the specific disease indication.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by aging populations, increased cancer incidence, and advances in therapeutic options. The competitive landscape is intense with numerous pharmaceutical and biotechnology companies.
Positioning
Karyopharm is positioned as an innovative oncology company focused on developing novel SINE compounds. Its competitive advantage lies in its unique mechanism of action and its approved indications.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Karyopharm's XPOVIO is positioned to capture a segment of the MM and DLBCL markets, as well as potentially expand into other indications.
Upturn SWOT Analysis
Strengths
- Approved product (XPOVIO)
- Novel SINE technology platform
- Experienced management team
Weaknesses
- Reliance on a single product
- High operating expenses
- Limited commercial infrastructure
Opportunities
- Expansion of XPOVIO into new indications
- Partnerships and collaborations
- Development of new SINE compounds
Threats
- Competition from established therapies
- Regulatory hurdles
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- BMY
- AMGN
- JNJ
- NVS
Competitive Landscape
Karyopharm faces stiff competition from larger pharmaceutical companies with established oncology portfolios. Karyopharm's advantage lies in its novel SINE technology, but it needs to successfully navigate the competitive landscape to achieve sustained growth. Note: Market share percentages are estimations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the commercialization of XPOVIO. However, growth has been volatile due to market acceptance and competition.
Future Projections: Future growth is dependent on the successful expansion of XPOVIO into new indications and the development of new products.
Recent Initiatives: Recent initiatives include ongoing clinical trials, expansion of the commercial team, and partnerships.
Summary
Karyopharm is a developing company with an approved product and novel technology. It faces challenges related to competition, commercial execution, and financial stability. Expansion into new indications and strategic partnerships are crucial for future success. The company has a unique mechanism with XPOVIO which gives it a unique positioning.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share estimations are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Karyopharm Therapeutics Inc
Exchange NASDAQ | Headquaters Newton, MA, United States | ||
IPO Launch date 2013-11-06 | President, CEO & Director Mr. Richard A. Paulson M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 279 | Website https://www.karyopharm.com |
Full time employees 279 | Website https://www.karyopharm.com | ||
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.